TGFB1 and hepatocellular carcinoma: There is indirect evidence supporting this claim that in patients with hepatocellular carcinoma, carriers of the -509CC genotype had statistically significant higher levels of circulating TGF-β1 and liver tumor tissue TGF-β1 mRNA expression compared with those with the -509TT genotype [17].